Compare YieldMax NVDA Option Income Strategy ETF (NVDY) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax NVDA Option Income Strategy ETF vs Novo Nordisk A/S — how do they compare? YieldMax NVDA Option Income Strategy ETF trades at $13.08, while Novo Nordisk A/S trades at $46.49 (market cap $207.85B). The key difference: Novo Nordisk A/S pays a 3.81% dividend while YieldMax NVDA Option Income Strategy ETF pays none, and Novo Nordisk A/S is trading nearer its 52-week high, YieldMax NVDA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| NVDY | NVO | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $17.96 | $63.98 |
52-Week Low | $11.58 | $35.29 |
Market Cap | — | $207.85B |
Enterprise Value | — | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVDY (YieldMax NVDA Option Income Strategy ETF) trades at $13.06, up 2.59% today with a bullish technical signal. The ETF generates weekly dividend distributions through options strategies on NVIDIA stock, though recent news highlights concerns about opportunity cost versus direct NVIDIA ownership. Technical indicators show mixed signals with RSI suggesting mild overbought conditions while moving averages remain bullish.
The outlook balances high income generation against capped upside potential. Investment opportunity lies in consistent weekly distributions, while primary risks include underperformance versus NVIDIA's explosive growth and the fund's strategy of selling call options that limit participation in NVIDIA's strongest rallies. The ETF appeals to income-focused investors willing to trade growth potential for regular cash flow.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
